Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
The study is testing a new treatment for high-risk myeloma, which is a type of blood cancer. The treatment includes three drugs: belantamab mafodotin (a special antibody with chemotherapy), pomalidomide (a chemotherapy drug), and dexamethasone (an anti-inflammatory drug). These drugs work together to target and kill cancer cells. The study aims to check how well this combination works and how safe it is for patients.
Patients will receive these treatments in cycles of 28 days. After finishing the treatment, they will have check-ups every 3 months. The study is for adults who have already had a stem cell transplant and meet certain health requirements.
- Participants may need to attend multiple clinic visits for treatments.
- There may be risks or side effects from the treatment.
- Eligibility includes having undergone a stem cell transplant recently and meeting specific health conditions.
Study details
NCT05208307
Emory University
11 July 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.